Please login to the form below

Not currently logged in
Email:
Password:

Tregs

This page shows the latest Tregs news and features for those working in and with pharma, biotech and healthcare.

Merck to acquire Pandion Therapeutics for $1.85bn

Merck to acquire Pandion Therapeutics for $1.85bn

Leading Pandion’s pipeline is an engineered IL-2 mutein fused to a protein backbone – known as PT101 – that is designed to selectively activate and expand regulatory T cells (Tregs) for ... Tregs can inhibit the activity of several different

Latest news

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Although described as an acquisition, the deal covers two products, including an anti-CD25 antibody that depletes regulatory T‐cells (Tregs) while preserving IL‐2 binding and signalling on effector ... Tregs) while preserving effector T‐cells (Teffs

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...